With accelerated population ageing and the growing prevalence of multimorbidity, polypharmacy in older adults has become a major challenge for medication safety and treatment effectiveness.
BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by ...